Clinical relevance of MMP-9 in terms of neoplasm growth, invasion and metastasis in thyroid, breast and colorectal cancer


  • V. Hari Kumar Department of General Surgery, Deccan College of Medical Sciences, Kanchanbagh, Hyderabad, Telangana, India
  • Omar Bin Hasan Department of General Surgery, Deccan College of Medical Sciences, Kanchanbagh, Hyderabad, Telangana, India



Carcinoma, Expression, MMP-9, Prognosis


Background: Cancer cells invade and metastasis commonly. This poses challenge in cancer management. MMP-9 can be clinically useful to predict the prognosis of the patients. Objective was to study clinical relevance of MMP-9 in terms of neoplasm growth, invasion and metastasis in Thyroid, Breast and Colorectal cancer.

Methods: A hospital based cross sectional study was carried out in Department of General Surgery, Kamineni Institute of Medical Sciences, Narketpally for a period of two years. A total of 30 cases of carcinoma cases were studied. Out of these carcinoma cases, 10 were of gastrointestinal malignancy, 10 were of thyroid malignancy and 10 were of breast carcinoma.

Results: For breast carcinoma, maximum cases were in the age group of 46-50 years (40%), for thyroid carcinoma, maximum cases were seen in the age group of more than 55 years (40%), for colo-rectal carcinoma, maximum cases were above the 50 years of age. For breast carcinoma, maximum cases were in stage III B (70%), for thyroid carcinoma, in III stage (60%) and for colo-rectal carcinoma, in Dukes C1 stage (60%). In breast cancer the positivity of MMP-9 was 66.7% in stage IIIA and it increased to 85.7% in stage IIIB. For thyroid cancer the positivity increased from 33.3% in stage III to 75% for stage IV A. In case of colo-rectal cancer, the positivity of MMP-9 expression increased from 66.7% for stage Dukes C 1 to 75% in stage Dukes C2 stage. Thus, for all types of carcinoma, the expression of MMP-9 increased with advancement of the stage.

Conclusions: MMP-9 is a gelatinase which degrades extra cellular matrix and helps in tumor spread. It is expressed more in advanced stages of the malignant disease. It correlates with prognosis of the patient.


Egeblad M, Werb Z. New functions for the matrix metalloproteinase in cancer progression. Natl Rev Cancer. 2002;2:161-74.

Lopez-Otin C, Overall CM. Protease degradomics: A new challenge for proteomics. Natl Rev Mol Cell Biol. 2001;3:509-19.

St-Pierre Y. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin Ther Targets. 2011;8(5):473-89.

Maruyama S, Yamamichi I, Kawata R, Shimada T, Shinomiya T, Murakami Y, et al. Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer. Nihon Jibiinkoka Gakkai Kaiho 2000;103(5):499-505.

Wang T, Jiang CX, Li Y. Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid. Zhonghua Bing Li Xue Za Zhi 2009;38(12):824-8.

Mitmaker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, et al. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surg. 2011;149(4):504-11.

Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 1991;51:439-44.

Zucker S, Lysik RM, Zarrabi MH, Moll U. Collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993;53:140-6.

Onisto M, Garbisa S, Caenazzo C, Freda MP, Di Francesco C, Nitti D, et al. Reverse transcription polymerase chain reaction phenotyping of metalloproteinase and inhibitors involved in tumor matrix invasion. Diagn Mol Pathol. 1993;2:74-80.

Dukes EC. The classification of cancer of the rectum. J Pathol Bacteriol. 1932;35:323-32.

Delektorskaya VV, Kushlinskii NE. Clinical significance of the content of biomolecular markers in invasive front of colon carcinomas. Bull Exp Biol Med. 2011;150(3):368-71.

Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56(1):190-6.

Dragutinovic V, Izrael-Zivkovic L, Radovanovic N. Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Dig Dis Sci. 2009;54(6):1203-7.

Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ. Gelatinase (MMP-2 and MMP-9) expression in gastrointestinal malignancy. Br J Cancer. 1998;78(11):1495-502.

Kong L, Sun JW, Zhang CH. The expression of integriαvβ6 and MMP-9 in gastric cancer and the correlation with clinicopathologic characteristic. Chinese J Cellular Molecular Immunol. 2011;27(1):92-4.






Original Research Articles